title: Initial experience with golimumab in clinical practice for ulcerative colitis.
abstract: BACKGROUND
  Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.
  
  
  OBJECTIVE
  To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice.
  
  
  METHODS
  Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg.
  
  
  RESULTS
  Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%.
  
  
  CONCLUSIONS
  In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe therapy, given that there were no adverse effects in the patients studied.
authors.affiliation: Digestivo, H Universitario Virgen Macarena, España.
authors.forename: Luisa
authors.initials: L
authors.lastname: Castro-Laria
authors.affiliation: Digestivo, H. Universitario Virgen Macarena, España.
authors.forename: Federico
authors.initials: F
authors.lastname: Argüelles-Arias
authors.affiliation: Aparato Digestivo, Hospital Universitario Reina Sofía - Córdoba, España.
authors.forename: Valle
authors.initials: V
authors.lastname: García-Sánchez
authors.affiliation: Aparato Digestivo, Hospital Universitario Reina Sofía - Córdoba, España.
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Benítez
authors.affiliation: Digestivo, Complejo Hospitalario de Jaén, España.
authors.forename: Ramón
authors.initials: R
authors.lastname: Fernández-Pérez
authors.affiliation: Digestivo, Complejo Hospitalario de Jaén, España.
authors.forename: Ana María
authors.initials: AM
authors.lastname: Trapero-Fernández
authors.affiliation: Digestivo, Hospital de Poniente, España.
authors.forename: Francisco
authors.initials: F
authors.lastname: Gallardo-Sánchez
authors.affiliation: Digestivo, Hospital Juan Ramón Jiménez, España.
authors.forename: Héctor
authors.initials: H
authors.lastname: Pallarés-Manrique
authors.affiliation: Digestivo, Hospital Virgen de las Nieves, España.
authors.forename: María
authors.initials: M
authors.lastname: Gómez-García
authors.affiliation: Digestivo, Hospital Virgen de las Nieves, España.
authors.forename: María José
authors.initials: MJ
authors.lastname: Cabello-Tapia
authors.affiliation: Digestivo, Hospital Infanta Elena, España.
authors.forename: Aurora
authors.initials: A
authors.lastname: Talavera-Fabuel
authors.affiliation: Digestivo, Hospital Infanta Elena, España.
authors.forename: Ana
authors.initials: A
authors.lastname: Bejarano-García
authors.affiliation: Aparato Digestivo, Hospital Virgen del Rocío - Sevilla, España.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Leo-Carnerero
authors.affiliation: Digestivo, Hospital Torrecárdenas, España.
authors.forename: Álvaro
authors.initials: Á
authors.lastname: Hernández-Martínez
authors.affiliation: Aparato Digestivo, Hospital Universitario Virgen Macarena, España.
authors.forename: Ángel
authors.initials: Á
authors.lastname: Caunedo-Álvarez
authors.affiliation: Hospital Universitario Virgen Macarena.
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Herrerías-Gutiérrez
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab